|
|
|
|
|
Highlights from the 36th Annual EAU Virtual Congress |
|
|
|
| Upper Urothelial Cancer: Established Treatment and Guidelines |
| Arnulf Stenzl, MD |
| The Urology Beyond Europe thematic sessions included the Joint Session of the European Association of Urology (EAU) and the Arab Association of Urology, as well as a presentation by Arnulf Stenzl discussing established treatment and guidelines for upper tract urothelial carcinoma. |
|
|
|
|
|
| Neoadjuvant Chemotherapy in Upper Urothelial Cancer |
| Mohammad Abufaraj, MD |
| Mohammad Abufaraj discussed neoadjuvant chemotherapy for upper tract urothelial carcinoma at the joint session of the European Association of Urology (EAU) and the Arab Association of Urology. |
|
|
|
|
|
| Update on EAU-Guidelines on Management of Upper Tract Urothelial Cancer
|
| Morgan Roupret, MD, Ph.D.
|
| Morgan Roupret highlights the updated guidelines on the management of upper tract urothelial carcinoma. This update was published in 2020 in European Urology. Dr. Roupret emphasizes that among patients with upper tract urothelial carcinoma, there is new hope for the future.
|
|
|
|
|
|
| Will MRI Transform the Management of Muscle Invasive Bladder Cancer? |
| Valeria Panebianco, MD |
| The joint session of the European Association of Urology and the Maghreb Union Countries included a bladder cancer session and presentation by Dr. Valeria Panebianco discussing the role of MRI in the management of muscle invasive bladder cancer. |
|
|
|
|
|
| How Do I Prepare My Patients for Cystectomy?
|
| Imad Ziouziou, MD, Ph.D.
|
| Imad Ziouziou presented on the preparation of patients for radical cystectomy. Dr. Ziouziou emphasized that we must check everything before taking the decision to proceed with radical cystectomy, including detecting frailty, anticipating surgical complications (inform the patient), anticipate general complications in collaboration with anesthetist and other colleagues, check that the environment (hospital) is appropriate, and implement ERAS. The decision ultimately comes down to a shared decision-making process with the patient, oncologists, anesthetists, cardiologists, and perhaps other surgical colleagues.
|
|
|
|
|
|
|
|
|
|
|
| How Relevant Are Advances in Optics in the Visualization of NMIBC? |
| Mohamed Tetou |
| Mohamed Tetou discusses advances in optics in the visualization of non-muscle invasive bladder cancer. White-light cystoscopy is the diagnostic standard for the detection of bladder cancer, however, it is often challenging secondary to the necessity of detecting small papillary and carcinoma in situ lesions. |
|
|
|
|
|
| What Are the Main Steps to Optimal TURBT? |
| Maximilian Burger, MD |
| Maximilian Burger presented on the main steps of an optimal transurethral resection of a bladder tumor (TURBT). These main steps to an optimal TURBT are to (i) appreciate the patient, (ii) appreciate the importance of the procedure, and (iii) appreciate the management that proceeds after the TURBT is performed. |
|
|
|
|
|
| BCG, Maintenance, or Else? We Shouldn't Deviate from the Guidelines for the Sake of Patient’s Safety |
| Wassim Kassouf, MD |
| Wassim Kassouf presented on avoiding deviation from the guidelines for BCG maintenance therapy for the sake of patient’s safety at the 2021 European Association Urology (EAU) annual meeting’s joint session between the EAU and Canadian Urological Association (CUA). Dr. Kassouf emphasized that many of his recommendations will be based on the new CUA Guidelines on the management of non-muscle invasive bladder cancer 2021, which is currently in press at CUAJ. |
|
|
|
|
|
| BCG, Maintenance, or Else? There Are Data for Shorter Maintenance Due to Different Therapies, Side Effects and Patients' Compliance |
| J. Alfred Witjes, MD, Ph.D. |
| The Canadian Urological Association joint session with the European Association Urology (EAU) at the 2021 annual EAU virtual meeting included a presentation by J. Alfred Witjes who discussed shorter maintenance regimens for patients receiving BCG therapy. When the guidelines discuss BCG “and/or alternative treatments”, this is an issue for patients with higher-end intermediate-risk NMIBC, high-risk NMIBC, the highest risk patients, and those that are failing BCG. |
|
|
|
|
|
| Treatment Challenges to BCG Unresponsive Non-Muscle Invasive Bladder Cancer |
| Keisuke Shigeta, MD |
| Keisuke Shigeta from Tokyo, Japan joined the Joint Session of the European Association of Urology and Japanese Urological Association at the 2021 EAU annual meeting to discuss treatment challenges in BCG unresponsive non-muscle invasive bladder cancer (NMIBC). Radical cystectomy is the only promising treatment option for cure in BCG unresponsive NMIBC patients, however clinical trials including intravesical PD-1/PD-L1 blockade are ongoing to provide bladder preserving options for these patients. |
|
|
|
|
|
|
|
| To view our full coverage of the 2021 EAU Virtual Congress, visit the Conference Coverage section on UroToday.com
|
|
|
|
|
|
|
 |
|
|
|
|
